摘要
目的:探讨小分子化合物表皮生长因子受体(EGFR)-酪氨酸激酶抑制剂(TKI)联合放化疗治疗EGFR基因突变型非小细胞肺癌(NSCLC)的临床效果。方法:选取2019年9月—2022年9月武汉科技大学医学院收治的EGFR基因突变型NSCLC患者96例作为研究对象,利用随机数字表分为对照组(采用常规放化疗)和研究组(在对照组基础上加用EGFR-TKI方案治疗),各48例。比较两组临床疗效、血液因子水平、预后及治疗安全性情况。结果:研究组客观缓解率、疾病控制率高于对照组(P<0.05);治疗后,两组细胞角蛋白19片段抗原21、癌胚抗原、金属基质蛋白酶-9、血管内皮生长因子水平下降,且研究组低于对照组(P<0.05);随访后,研究组与对照组的中位无进展生存期分别为21个月、18个月,中位总生存期分别为27个月、22个月;两组治疗安全性比较,差异无统计学意义(P>0.05)。结论:小分子化合物EGFR-TKI联合放化疗治疗EGFR基因突变型NSCLC的效果显著,可有效降低患者血液相关因子水平,控制肿瘤进展和延长总生存期,安全性较高。
Objective:To explore the clinical effects of small molecule compounds epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitor(TKI)combined with chemoradiotherapy in the treatment of EGFR-mutant non-small cell lung cancer(NSCLC).Methods:Ninety-six patients with EGFR gene-mutated NSCLC admitted to the School of Medicine of Wuhan University of Science and Technology(WUST)from September 2019 to September 2022 were selected as the study subjects,and were divided into the control group(treated with conventional radiotherapy)and the study group(treated with EGFR-TKI regimen on the basis of the control group)by using a randomized numerical table,each with forty-eight cases.The clinical efficacy,blood factor levels,prognosis and treatment safety were compared between the two groups.Results:The objective remission rate and disease control rate of the study group were higher than those of the control group(P<0.05);after treatment,the levels of cytokeratin 19 fragment antigen 21,carcinoembryonic antigen,metallo-matrix protease-9,and vascular endothelial growth factor decreased in the two groups and were lower in the study group than in the control group(P<0.05);after follow-up,the median progression-free survival of the study group and the control group was twenty-one months and eighteen months,respectively,and the median overall survival was twenty-seven months and twenty-two months,respectively;comparing the safety of treatment between the two groups,the difference was not statistically significant(P>0.05).Conclusion:Small molecule compound EGFR-TKI combined with radiotherapy is effective in the treatment of EGFR gene mutated NSCLC,which can effectively reduce the level of patients'blood-related factors,control tumor progression and prolong overall survival,with high safety.
作者
周梅英
邓鹏
李幸幸
向世强
Zhou Meiying;Deng Peng;Li Xingxing;Xiang Shiqiang(The School of Medicine of Wuhan University of Science and Technology,Wuhan 430081,Hubei Province,China;Wuhan Qianmai Medical Laboratory,Wuhan 430000,Hubei Province,China)
出处
《中外医药研究》
2024年第24期24-26,共3页
JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH
